Skip to main content
Figure 6 | Breast Cancer Research

Figure 6

From: Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy

Figure 6

Therapeutic effects of TBG-siCDK11 and TBG-siCK2 treatment in MDA-MB-231 xenograft tumors. (A) Primary tumor volumes are shown following intravenous treatments at 0.01 mg/kg TBG-siCDK11, TBG-siCK2, or TBG-siCON1 on days 1, 4 and 7 (indicated by arrows). Means ± standard errors (SEs) are presented (TBG-siCDK11 and TBG-siCK2, n = 6; TBG-siCON1, n =7). *P <0.05, **P <0.01. (B) Primary tumor masses are shown following treatments as described in (A). Thick line, mean; thin bar, SE (TBG-siCDK11 and TBG-siCK2, n = 6; TBG-siCON1, n = 7). # P <0.05. (C) Masses of the mice throughout the study for each treatment group. Means are presented and error bars represent the SE. (D) Percentage of Ki-67-positive cells was analyzed as described in Materials and methods and is shown graphically. Least-squares means are presented and error bars represent SE. **P <0.01. CDK, cyclin-dependent kinase; CK2, casein kinase 2; si, small interfering; TBG, tenfibgen.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us